Literature DB >> 16887141

Efficient and reproducible large-scale isolation of human CD4+ CD25+ regulatory T cells with potent suppressor activity.

David G Wichlan1, Philippa L Roddam, Paul Eldridge, Rupert Handgretinger, Janice M Riberdy.   

Abstract

CD4+ CD25+ regulatory T cells have been the subject of intense investigation and have been shown to modulate immune responses in the settings of autoimmunity, cancer and transplantation. The assessment and optimization of purification schemes for specific cellular subtypes such as CD4+ CD25+ regulatory T cells is a critical consideration in developing cell-based therapies in the clinical setting. In the following studies, different strategies for magnetic isolation are compared and the parameters which affect the overall potency of purified human CD4+ CD25+ regulatory T cells are discussed. The data demonstrate that large-scale magnetic isolation can be used to efficiently and reproducibly purify human CD4+ CD25+ regulatory T cells capable of modulating alloreactive T cell responses. The ability to rapidly purify the desired cells from peripheral blood suggests that magnetic isolation may be a suitable alternative to cell sorting for clinical settings, where large numbers of CD4+ CD25+ regulatory T cells may be necessary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887141     DOI: 10.1016/j.jim.2006.06.014

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood.

Authors:  Huahua Fan; Jie Yang; Jun Hao; Yana Ren; Liang Chen; Guiping Li; Rufeng Xie; Yiming Yang; Feng Gao; Mingyao Liu
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  In vitro Treg suppression assays.

Authors:  Lauren W Collison; Dario A A Vignali
Journal:  Methods Mol Biol       Date:  2011

3.  In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

Authors:  James C Lee; Erik Hayman; Hollie J Pegram; Elmer Santos; Glenn Heller; Michel Sadelain; Renier Brentjens
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

4.  Clinical grade isolation of regulatory T cells from G-CSF mobilized peripheral blood improves with initial depletion of monocytes.

Authors:  Pritesh Patel; Dolores Mahmud; Youngmin Park; Kazumi Yoshinaga; Nadim Mahmud; Damiano Rondelli
Journal:  Am J Blood Res       Date:  2015-12-25

Review 5.  Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.

Authors:  Nicholas A Zwang; Joseph R Leventhal
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

Review 6.  Promoting transplantation tolerance; adoptive regulatory T cell therapy.

Authors:  N Safinia; J Leech; M Hernandez-Fuentes; R Lechler; G Lombardi
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

Review 7.  Improving engraftment and immune reconstitution in umbilical cord blood transplantation.

Authors:  Robert Danby; Vanderson Rocha
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

8.  Chronically HIV-1 Infected Patients Exhibit Low Frequencies of CD25+ Regulatory T Cells.

Authors:  Cesar Mauricio Rueda Rios; Paula Andrea Velilla; Maria Teresa Rugeles
Journal:  Open Virol J       Date:  2012-04-11

9.  Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy.

Authors:  Jorieke H Peters; Luuk B Hilbrands; Hans J P M Koenen; Irma Joosten
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

10.  Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation.

Authors:  Jorieke H Peters; Frank W Preijers; Rob Woestenenk; Luuk B Hilbrands; Hans J P M Koenen; Irma Joosten
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.